ALPS Advisors’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-788
| Closed | -$180K | – | 801 |
|
|
2020
Q1 | $180K | Sell |
788
-92
| -10% | -$21K | ﹤0.01% | 781 |
|
|
2019
Q4 | $466K | Buy |
880
+18
| +2% | +$9.53K | ﹤0.01% | 520 |
|
|
2019
Q3 | $371K | Sell |
862
-42
| -5% | -$18.1K | ﹤0.01% | 543 |
|
|
2019
Q2 | $1.08M | Sell |
904
-138
| -13% | -$164K | 0.01% | 316 |
|
|
2019
Q1 | $1.3M | Buy |
1,042
+45
| +5% | +$56.1K | 0.01% | 275 |
|
|
2018
Q4 | $944K | Buy |
997
+235
| +31% | +$223K | 0.01% | 314 |
|
|
2018
Q3 | $1.1M | Buy |
762
+145
| +24% | +$209K | 0.01% | 364 |
|
|
2018
Q2 | $995K | Buy |
617
+156
| +34% | +$252K | 0.01% | 340 |
|
|
2018
Q1 | $747K | Buy |
461
+80
| +21% | +$130K | 0.01% | 367 |
|
|
2017
Q4 | $639K | Buy |
+381
| New | +$639K | ﹤0.01% | 359 |
|